Pharvaris N.V. (PHVS), a clinical-stage company developing novel, oral therapies to treat and prevent hereditary angioedema attacks, is slated to make a poster presentation at the Western Society of Allergy, Asthma & Immunology Annual Meeting on Feb.4, 2024.
One of the posters is about the efficacy and safety of bradykinin B2 receptor antagonism with Deucrictibant immediate-release capsule (also known as PHVS416) for the treatment of hereditary angioedema (HAE) attacks based on findings from RAPIDe-1 trial.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.